To include your compound in the COVID-19 Resource Center, submit it here.

Remicade infliximab: Phase III data

Patients who achieved a clinical response at week 8 were randomized to receive 5 mg/kg Remicade every 8 weeks through week 46 (n=22) or every 12 weeks through week 42 (n=23). At week 54, a non-significantly greater proportion of patients receiving

Read the full 419 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers